Further studies on the role of immune checkpoints, including PD‐1/PD‐L1, TIM‐3, LAG‐3, and TIGIT, in the tumor microenvironment are needed to explore their potential as therapeutic targets. This evidence concerns the gene HAVCR2 and neoplasm.